Pulmonary Disease, Chronic Obstructive: all 4,252 studies

Page 11 of 43. Open to participants first (707), then studies with results posted, then the rest; newest registration first within each.

• A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance TherapyCompletedNCT02238483Phase 2Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236611Phase 4Results posted
• Aides in Respiration Health Coaching for COPDCompletedNCT02234284Not applicableResults posted
• A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02233543Phase 4Results posted
• Social Work Intervention Focused on TransitionsCompletedNCT02232126Not applicableResults posted
• Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02231177Phase 1Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT02207829Phase 3Results posted
• Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)CompletedNCT02202616Phase 4Results posted
• Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02196077Phase 2Results posted
• Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler DevicesCompletedNCT02184624Phase 4Results posted
• A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)CompletedNCT02184611Phase 3Results posted
• Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to TyvasoTerminatedNCT02178566Phase 2Results posted
• Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation TherapyCompletedNCT02173769Results posted
• Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPDCompletedNCT02165826Phase 3Results posted
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedNCT02164539Phase 2Results posted
• A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02164513Phase 3Results posted
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02155660Phase 3Results posted
• A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02153489Phase 4Results posted
• A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02152605Phase 3Results posted
• Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk SmokersCompletedNCT02148445Phase 3Results posted
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation HistoryCompletedNCT02138916Phase 3Results posted
• TOPIC Trial for COPDCompletedNCT02135432Early Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02130635Phase 2Results posted
• Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for ExacerbationsCompletedNCT02130193Phase 2Results posted
• Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsCompletedNCT02125734Phase 4Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2CompletedNCT02119286Phase 3Results posted
• PATient Navigator to rEduce ReadmissionsCompletedNCT02114515Not applicableResults posted
• A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02109172Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105974Phase 3Results posted
• Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105961Phase 3Results posted
• Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02105948Phase 3Results posted
• Comparative Effectiveness of a Peer-led O2 Infoline for Patients and CaregiversCompletedNCT02098369Phase 4Results posted
• Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary EventsCompletedNCT02096731Results posted
• To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of AirwaysCompletedNCT02085161Phase 3Results posted
• Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02077465Phase 1Results posted
• A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.CompletedNCT02075541Phase 2Results posted
• Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPDCompletedNCT02059434Phase 1Results posted
• Specialized Community Disease Management to Reduce Substance Use and Hospital ReadmissionsCompletedNCT02059005Not applicableResults posted
• Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPDCompletedNCT02055352Phase 4Results posted
• A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02040792Phase 2Results posted
• Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02036294Not applicableResults posted
• Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different InhalersCompletedNCT02030535Phase 2Results posted
• Integrating Care After Exacerbation of COPDCompletedNCT02021955Not applicableResults posted
• A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02014480Phase 3Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)CompletedNCT02006732Phase 3Results posted
• Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.CompletedNCT01996319Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD RegimenCompletedNCT01985334Phase 4Results posted
• A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01978145Phase 3Results posted
• Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)CompletedNCT01970878Phase 3Results posted
• Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsCompletedNCT01969721Phase 3Results posted
• Ventilator Adapters for Combivent RespimatTerminatedNCT01969539Phase 4Results posted
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.CompletedNCT01966107Phase 4Results posted
• Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)CompletedNCT01964352Phase 3Results posted
• Clinical Trials for Elderly Patients With Multiple DiseaseCompletedNCT01960907Not applicableResults posted
• BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic BronchitisCompletedNCT01958008Phase 1Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01957163Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• Efficacy and Safety of AQX-1125 in Unstable COPDCompletedNCT01954628Phase 2Results posted
• Early Assisted Discharge for COPD Exacerbations With Telemonitoring.CompletedNCT01951261Not applicableResults posted
• Ipratropium Bromide in Peri-Operative COPDCompletedNCT01943552Phase 4Results posted
• Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01937390Results posted
• Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD PatientsCompletedNCT01933984Not applicableResults posted
• Improving Communication About Serious IllnessCompletedNCT01933789Not applicableResults posted
• Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01922271Phase 4Results posted
• Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPDCompletedNCT01917331Phase 3Results posted
• Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01908140Phase 3Results posted
• The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on TiotropiumCompletedNCT01899742Phase 3Results posted
• Physical Training and Heart Rate Variability in COPDCompletedNCT01889563Not applicableResults posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01879410Phase 3Results posted
• DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01868009Phase 3Results posted
• Tadalafil for Pulmonary Hypertension Due to Chronic Lung DiseaseCompletedNCT01862536Phase 2Results posted
• Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)CompletedNCT01857323Phase 3Results posted
• Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)CompletedNCT01854658Phase 3Results posted
• Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)CompletedNCT01854645Phase 3Results posted
• Differentiating the Effects of Substance P and Beta-endorphinCompletedNCT01854177Not applicableResults posted
• Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01842360Phase 2/3Results posted
• COPD Assessment and Management Bundle Versus Usual CareCompletedNCT01833026Not applicableResults posted
• Acute Effects of a Flutter Device in COPDCompletedNCT01832961Not applicableResults posted
• A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01822899Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01817764Phase 3Results posted
• Preference Tiotropium Respimat Study in COPDCompletedNCT01810692Results posted
• Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary DiseaseCompletedNCT01809262Phase 2Results posted
• A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting BronchodilatorCompletedNCT01794780Phase 4Results posted
• Effect of Symbicort ® on GR in Sputum in COPDCompletedNCT01787097Phase 4Results posted
• QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)CompletedNCT01782326Phase 3Results posted
• Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification StudyCompletedNCT01780298Results posted
• The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPDCompletedNCT01777334Phase 3Results posted
• Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.CompletedNCT01772147Phase 3Results posted
• Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 WeeksCompletedNCT01772134Phase 3Results posted
• Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcgCompletedNCT01762800Phase 4Results posted
• Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus PlaceboTerminatedNCT01760304Phase 4Results posted
• A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese SubjectsCompletedNCT01751113Phase 4Results posted
• Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPDCompletedNCT01745848Phase 4Results posted
• Doxycycline for COPD in HIV-Infected PatientsCompletedNCT01744093Not applicableResults posted
• Early Warning SystemCompletedNCT01741480Not applicableResults posted
• LungVITamin D and OmegA-3 Trial (lungVITAL)Active, not recruitingNCT01728571Not applicableResults posted
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedNCT01727141Phase 3Results posted
• Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsCompletedNCT01727024Phase 4Results posted
• Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01721291Phase 4Results posted
• Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcgCompletedNCT01716520Phase 3Results posted

← Pulmonary Disease, Chronic Obstructive overview